Back to All Clinical Evidence
Evidence Category:
Advanced Therapies

Advanced Therapies

In this prospective trial, addition of a biofilm disrupting antimicrobial agent to NPWT reduced surface area and led to improved wound healing in 4/6 recalcitrant pressure ulcers

A reduction in wound area correlated with a reduction in bacterial burden as evidenced by fluorescence imaging (MolecuLight i:X)

The MolecuLight procedure enabled detection of bacteria build up in the NPWT sponges at the point-of-care

This study aimed to assess the efficacy and safety of a porcine peritoneum-derived matrix, a type of cellular and/or tissue product for treatment of DFUs

MolecuLight i:X imaging and measurement of bacterial protease activity (BPA) were performed weekly to evaluate bacterial load in wounds

Low bacterial loads, indicated by absence of fluorescence on MolecuLight i:X images and negative BPA, predicted wound healing

Fluorescence imaging was used to inform on the presence of bacterial loads in stage 3 and 4 pressure ulcers

These pressure ulcers underwent NPWT and treatment with a biofilm disrupting agent

In wounds where negative fluorescence images suggested lower bacterial levels, a reduction in wound surface area and volume was observed

This RCT used fluorescence imaging to evaluate the effects of cold atmospheric plasma on wound area of chronic wounds

Fluorescence images were used to visualize the bacterially colonized area and compare the area before and after

50.4 % reduction of bacterial load for Group 1 and 35.0 % for Group 2 compared to the day of study